Literature DB >> 2888115

Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQw1 and DQw3 alleles of the HLA-D region.

F Szafer, C Brautbar, E Tzfoni, G Frankel, L Sherman, I Cohen, S Hacham-Zadeh, W Aberer, G Tappeiner, K Holubar.   

Abstract

Pemphigus vulgaris in Israeli Ashkenazi and non-Ashkenazi Jews and in Austrian non-Jewish patients is strongly associated with the DR4 and DRw6 alleles of the HLA-D region class II genes. Restriction fragment length polymorphism analysis was undertaken with DQ beta, DQ alpha, and DR beta cDNA probes. Hybridization with the DQ beta probe identifies Pvu II, BamHI, and EcoRV fragments that absolutely discriminate pemphigus vulgaris patients from healthy DR-, DQ-, and ethnic-matched controls. In contrast the DQ alpha and DR beta probes failed to identify disease-specific restriction fragment length polymorphism fragments. These studies indicate that DQw1 and DQw3 polymorphisms carried by pemphigus vulgaris patients may be directly involved in predisposition to the disease or may be tightly linked to the susceptibility gene itself. To our knowledge, this is the first example of an HLA restriction fragment length polymorphism that is highly associated with susceptibility to autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888115      PMCID: PMC299114          DOI: 10.1073/pnas.84.18.6542

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  Clusters of HLA class II beta restriction fragments describe allelic series.

Authors:  D Cohen; I Le Gall; A Marcadet; M P Font; J M Lalouel; J Dausset
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

Review 4.  HLA-D region molecules restrict proliferative T cell responses to antigen.

Authors:  E Thorsby; E Berle; H Nousiainen
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Do identical HLA-DR3 genes convey susceptibility to celiac disease and insulin dependent diabetes mellitus?

Authors:  C Brautbar; J Zlotogora; N Laufer; T Cohen; E D Albert
Journal:  Tissue Antigens       Date:  1984-01

6.  HLA-and Gm-linked genes affecting the degradation rate of antigens (sheep red blood cells) endocytized by macrophages.

Authors:  L Legrand; L Rivat-Perran; C Huttin; J Dausset
Journal:  Hum Immunol       Date:  1982-02       Impact factor: 2.850

7.  cDNA clone for the heavy chain of the human B cell alloantigen DC1: strong sequence homology to the HLA-DR heavy chain.

Authors:  C Auffray; A J Korman; M Roux-Dosseto; R Bono; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

Review 8.  Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture.

Authors:  P I Terasaki; D Bernoco; M S Park; G Ozturk; Y Iwaki
Journal:  Am J Clin Pathol       Date:  1978-02       Impact factor: 2.493

9.  A membrane-filter technique for the detection of complementary DNA.

Authors:  D T Denhardt
Journal:  Biochem Biophys Res Commun       Date:  1966-06-13       Impact factor: 3.575

10.  HLA-DRw4 in pemphigus vulgaris patients in Israel.

Authors:  C Brautbar; M Moscovitz; T Livshits; S Haim; S Hacham-Zadeh; H A Cohen; R Sharon; D Nelken; T Cohen
Journal:  Tissue Antigens       Date:  1980-09
View more
  12 in total

Review 1.  Evolution of HLA class-II genes and haplotypes.

Authors:  J Silver
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 2.  Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.

Authors:  J R Stanley
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

3.  Medical genetics in Israel.

Authors:  R M Goodman; B Bonne-Tamir; A Adam; R Voss; G Bach; Y Shiloh; M B Katznelson; G Barkai; B Goldman; B Padeh
Journal:  J Med Genet       Date:  1989-03       Impact factor: 6.318

4.  Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris.

Authors:  A R Ahmed; R Wagner; K Khatri; G Notani; Z Awdeh; C A Alper; E J Yunis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  HLA-DQw7 is a disease severity marker in patients with rheumatoid arthritis.

Authors:  H A Stephens; L I Sakkas; R W Vaughan; I Teitsson; K I Welsh; G S Panayi
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

6.  HLA class II allelic variation and susceptibility to pemphigus vulgaris.

Authors:  S J Scharf; A Friedmann; C Brautbar; F Szafer; L Steinman; G Horn; U Gyllensten; H A Erlich
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 7.  T cell repertoire and autoimmune diseases.

Authors:  L Imberti; A Sottini; D Primi
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

8.  Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris.

Authors:  A R Ahmed; E J Yunis; K Khatri; R Wagner; G Notani; Z Awdeh; C A Alper
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

9.  Specific HLA-DQB and HLA-DRB1 alleles confer susceptibility to pemphigus vulgaris.

Authors:  S J Scharf; A Freidmann; L Steinman; C Brautbar; H A Erlich
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  The immunoglobulin heavy chain and disease association: application to pemphigus vulgaris.

Authors:  W T Gibson; M A Walter; A R Ahmed; C A Alper; D W Cox
Journal:  Hum Genet       Date:  1994-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.